Overview

This trial is active, not recruiting.

Condition influenza a virus infection
Treatment collection of anti-influenza a immune plasma
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Start date April 2010
End date January 2019
Trial size 200 participants
Trial identifier NCT01136057, IDCRP-046

Summary

Treatment options are limited for the treatment of influenza. This study will collect blood from people who have been exposed to the influenza virus or who have received a seasonal influenza vaccine. The blood plasma will be used in a future clinical trial to treat people hospitalized with influenza.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
collection of anti-influenza a immune plasma

Primary Outcomes

Measure
Collection of high antibody titer anti-influenza FFP
time frame: Collected at each study visit

Secondary Outcomes

Measure
Further define the hemagglutination inhibition (HAI) immune response in participants over time
time frame: Collected at each study visit

Eligibility Criteria

Male participants from 18 years up to 59 years old.

Inclusion Criteria: - Currently healthy males 18 - 59 years of age with a history suggestive of having anti-influenza antibodies (either or both of the following): 1. An influenza-like illness (e.g., fever, chills, malaise, cough, myalgias, nausea). Subjects must asymptomatic and must be afebrile for ≥ 7 days, and must enroll within 12 months of onset of illness. 2. Vaccinated with a licensed influenza vaccine. Enrollment must occur >14 days and < 12 months from date of vaccination. - Must be an adult male Department of Defense (DoD)/beneficiary - Sign informed consent and Health Insurance Portability and Accountability Act (HIPAA) document - A demonstrated H1N1 HAI titer of 1:160 or greater and H3N2 HAI titer of 1:40 or greater. - Must also meet all Standard-of-Care inclusion criteria for donation of blood or plasma at the FDA-licensed donor center prior to every donation session. More information on this criterion can be found in the protocol. Exclusion Criteria: - Donors that do not meet all Standard-of-Care FDA approved requirements for the donation of blood and production of FFP as determined by the FDA-licensed donor center prior to every donation session may be excluded from further participation in this study. Study exclusion will be determined by the principal investigator (PI) or lead investigator at the study site. - Donors that fail the Standard-of-Care screening and Blood Borne Pathogen screening for the following blood borne pathogens at the donor center will be excluded: 1. Anti-HIV-I/II 2. Anti-human T-lymphotropic virus (HTLV)-I/II 3. Anti-hepatitis C (HCV) 4. Anti-hepatitis B core antigen (HBc) 5. Anti-T. cruzi (enzyme immunoassay [EIA] for Chagas disease) (if required by the FDA-licensed donor center or becomes a nationwide FDA requirement) 6. Hepatitis B surface antigen (HBsAg) 7. Serologic test for syphilis 8. HIV nucleic acid test (NAT) 9. HCV NAT 10. West Nile virus (WNV) NAT - Participation in other medical research that includes: 1. Studies that are currently ongoing or will start during the duration of this study that require more than 60 mL of blood to be donated in any 56-day period of time 2. Administration of any unlicensed drug in the 3 months before study entry or during the duration of this study 3. Administration of any unlicensed vaccine in the 12 months before study entry or during the duration of this study, with the exception of unlicensed influenza vaccine

Additional Information

Official title A Pilot Study for Collection of High-Titer Anti-Influenza A Plasma
Principal investigator LCDR Nicholas Martin, USN, MSC
Description There is a concern that the influenza virus will become resistant to the standard of care, oseltamivir (commonly known as Tamiflu), as resistance to this medication has been observed in people infected with the seasonal influenza virus. Because of the possibility of drug resistance, additional treatment options for influenza are needed. The purpose of this study is to collect blood from people who have recovered from influenza or who have received a seasonal influenza vaccine. The blood will then be processed into Food and Drug Administration (FDA)-licensed fresh frozen plasma (FFP). In a future clinical trial, this plasma will be used as a treatment for people hospitalized with influenza. This study will enroll people who have recovered from influenza or received a seasonal influenza vaccine. Participants will donate blood at FDA-licensed blood donor centers up to three times during the 240-day study period.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID).